\-\ Texto\\:\\ \ \(0\)\
\-\ this\\ patient\\ was\\ found\\ to\\ have\\ c\\.\\ difficile\\ toxin\\ in\\ her\\ stool\\.\ \(0\)\
\-\ this\\ patient\\ was\\ managed\\ surgically\\ with\\ colectomy\\.\ \(0\)\
\-\ \\â\\€\\¢\\ dilated\\ transverse\\ colon\\ \\>\\ 5\\.5\\ cm\ \(0\)\
\-\ toxic\\ megacolon\\ \\(complication\\ of\\ ulcerative\\ colitis\\)\ \(0\)\
\-\ \\â\\€\\¢\\ ileus\ \(0\)\
\-\ \\â\\€\\¢\\ pseudomembranous\\ colitis\ \(0\)\
\-\ \\â\\€\\¢\\ toxic\\ megacolon\\ \\(complication\\ of\\ ulcerative\\ colitis\\)\ \(0\)\
\-\ \\â\\€\\¢\\ clostridium\\ difficile\\ colitis\ \(0\)\
\-\ \\â\\€\\¢\\ crohn\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ cytomegalovirus\\ infection\ \(1\)\
\-\ \\â\\€\\¢\\ drug\\-induced\\ colitis\ \(1\)\
\-\ \\â\\€\\¢\\ ischemic\\ colitis\ \(1\)\
\-\ 57\\ y\\.o\\.\\ woman\\ admitted\\ for\\ two\\ weeks\\ history\\ of\\ abdominal\\ pain\\ and\\ eight\\ dark\\,\\ loose\\ stools\\ per\\ day\\.\\ patient\\ has\\ an\\ eight\\-year\\ history\\ of\\ ulcerative\\ colitis\\.\\ patient\\ was\\ initially\\ managed\\ medically\\ for\\ an\\ ulcerative\\ colitis\\ exacerbation\\.\\ initial\\ acute\\ abdominal\\ series\\ obtained\\ on\\ hospital\\ day\\ 2\\ \\(films\\ 1\\-3\\)\\.\\ the\\ second\\ acute\\ abdominal\\ series\\ \\(films\\ 4\\-6\\)\\ was\\ obtained\\ following\\ greatly\\ increased\\ abdominal\\ pain\\,\\ fever\\,\\ and\\ abdominal\\ distention\\.\ \(0\)\
\-\ toxic\\ megacolon\\ is\\ a\\ well\\-known\\ complication\\ of\\ chronic\\ ulcerative\\ colitis\\,\\ but\\ it\\ can\\ also\\ present\\ in\\ association\\ with\\ crohn\\&\\#34\\;s\\ disease\\,\\ psuedomembranous\\ colitis\\,\\ amebic\\ colitis\\,\\ and\\ other\\ infectious\\ causes\\.\\ marked\\ dilation\\ of\\ the\\ colon\\ is\\ obvious\\ in\\ these\\ patients\\.\\ the\\ wall\\ of\\ the\\ colon\\ becomes\\ extremely\\ thin\\,\\ friable\\,\\ and\\ susceptible\\ to\\ spontaneous\\ perforation\\.\\ distention\\ is\\ usually\\ best\\ noted\\ in\\ the\\ transverse\\ colon\\ of\\ a\\ supine\\ patient\\.\\ toxic\\ megacolon\\ is\\ defined\\ as\\ distention\\ of\\ the\\ colon\\ \\(\\>5\\.5cm\\)\\.\\ pseudopolypoid\\ projections\\ are\\ frequently\\ noted\\.\\ spontaneous\\ perforation\\ of\\ the\\ colon\\ is\\ the\\ major\\ complication\\.\\ because\\ of\\ the\\ risk\\ of\\ perforation\\ barium\\ enema\\ is\\ absolutely\\ contraindicated\\.\\ \ \(0\)\
\-\ this\\ patient\\ was\\ also\\ found\\ to\\ have\\ c\\.\\ difficile\\ toxin\\ in\\ her\\ stool\\.\\ positive\\ c\\.\\ difficile\\ toxin\\ the\\ stool\\ with\\ associated\\ acute\\ abdominal\\ symptoms\\ is\\ diagnostic\\ for\\ psuedomembranous\\ colitis\\.\\ \\ the\\ combination\\ of\\ chronic\\ ulcerative\\ colitis\\ and\\ psuedomembranous\\ colitis\\ raises\\ interesting\\ questions\\ as\\ to\\ the\\ true\\ etiology\\ of\\ her\\ development\\ of\\ toxic\\ megacolon\\.\ \(0\)\
\-\ this\\ patient\\ was\\ managed\\ surgically\\ with\\ colectomy\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\.lrc1\\.usuhs\\.edu\\/pmc\\/articles\\/pmc3134807\\/\\?tool\\=pubmed\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ colitis\\:\\ 0\\.19651909145179547\ \(0\)\
\-\ megacolon\\:\\ 0\\.10514609213680304\ \(0\)\
\-\ ulcerative\\:\\ 0\\.09787226216730581\ \(0\)\
\-\ difficile\\:\\ 0\\.07926100415126082\ \(0\)\
\-\ toxic\\:\\ 0\\.07498287326640986\ \(0\)\
\-\ psuedomembranous\\:\\ 0\\.07295543032999897\ \(0\)\
\-\ colon\\:\\ 0\\.06028621993692825\ \(0\)\
\-\ toxin\\:\\ 0\\.05944575311344561\ \(0\)\
\-\ complication\\:\\ 0\\.05018617497823026\ \(0\)\
\-\ c\\.\\:\\ 0\\.04441003664423899\ \(0\)\
\-\ stool\\:\\ 0\\.042257286465208266\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.042224937617853266\ \(0\)\
\-\ managed\\:\\ 0\\.041281533402308904\ \(0\)\
\-\ distention\\:\\ 0\\.04102116630464496\ \(0\)\
\-\ perforation\\:\\ 0\\.039491118109310476\ \(0\)\
\-\ abdominal\\:\\ 0\\.03836980667285237\ \(0\)\
\-\ colectomy\\:\\ 0\\.0358221861072472\ \(0\)\
\-\ crohn\\:\\ 0\\.027347444203096642\ \(0\)\
\-\ eight\\-year\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ pseudopolypoid\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ absolutely\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ \\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\.lrc1\\.usuhs\\.edu\\/pmc\\/articles\\/pmc3134807\\/\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ tool\\=pubmed\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ surgically\\:\\ 0\\.025909473378648858\ \(0\)\
\-\ series\\:\\ 0\\.025456109176638698\ \(0\)\
\-\ spontaneous\\:\\ 0\\.02387547716565388\ \(0\)\
\-\ her\\:\\ 0\\.023078547830703015\ \(0\)\
\-\ 5\\.5cm\\:\\ 0\\.02224318581690601\ \(0\)\
\-\ well\\-known\\:\\ 0\\.021575091351893408\ \(0\)\
\-\ films\\:\\ 0\\.021121265827975827\ \(0\)\
\-\ clostridium\\:\\ 0\\.021029218427360608\ \(0\)\
\-\ drug\\-induced\\:\\ 0\\.021029218427360608\ \(0\)\
\-\ amebic\\:\\ 0\\.02056768944584187\ \(0\)\
\-\ friable\\:\\ 0\\.02056768944584187\ \(0\)\
\-\ transverse\\:\\ 0\\.020517644875149687\ \(0\)\
\-\ cytomegalovirus\\:\\ 0\\.01949980039213309\ \(0\)\
\-\ acute\\:\\ 0\\.018951011938082293\ \(0\)\
\-\ pseudomembranous\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ 1\\-3\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ susceptible\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ questions\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ obtained\\:\\ 0\\.018190814974514025\ \(0\)\
\-\ contraindicated\\:\\ 0\\.01809260389738538\ \(0\)\
\-\ patient\\:\\ 0\\.017952525498247652\ \(0\)\
\-\ raises\\:\\ 0\\.0179110930536236\ \(0\)\
\-\ was\\:\\ 0\\.01775348842300036\ \(0\)\
\-\ greatly\\:\\ 0\\.01773996007805489\ \(0\)\
\-\ 5\\.5\\:\\ 0\\.017424509432372778\ \(0\)\
\-\ 4\\-6\\:\\ 0\\.017424509432372778\ \(0\)\
\-\ medically\\:\\ 0\\.017278431096536154\ \(0\)\
\-\ projections\\:\\ 0\\.01713914961259935\ \(0\)\
\-\ stools\\:\\ 0\\.017006060503105835\ \(0\)\
\-\ \\>\\:\\ 0\\.017001003081847692\ \(0\)\
\-\ eight\\:\\ 0\\.016756414967360172\ \(0\)\
\-\ day\\:\\ 0\\.0162452684392391\ \(0\)\
\-\ found\\:\\ 0\\.01612590188294678\ \(0\)\
\-\ exacerbation\\:\\ 0\\.015925182223053946\ \(0\)\
\-\ ileus\\:\\ 0\\.015749013061308638\ \(0\)\
\-\ interesting\\:\\ 0\\.015132689545727353\ \(0\)\
\-\ loose\\:\\ 0\\.014866379707354611\ \(0\)\
\-\ extremely\\:\\ 0\\.014563696722709792\ \(0\)\
\-\ chronic\\:\\ 0\\.014413111574293414\ \(0\)\
\-\ supine\\:\\ 0\\.014288823820754337\ \(0\)\
\-\ enema\\:\\ 0\\.014288823820754337\ \(0\)\
\-\ true\\:\\ 0\\.014037077960842536\ \(0\)\
\-\ dark\\:\\ 0\\.013989172747230437\ \(0\)\
\-\ 57\\:\\ 0\\.01394202197786475\ \(0\)\
\-\ becomes\\:\\ 0\\.013388362281774894\ \(0\)\
\-\ obvious\\:\\ 0\\.012921283693521657\ \(0\)\
\-\ combination\\:\\ 0\\.012888200351645656\ \(0\)\
\-\ 34\\:\\ 0\\.012697028279829688\ \(0\)\
\-\ ischemic\\:\\ 0\\.01245975471200292\ \(0\)\
\-\ association\\:\\ 0\\.012431375239085125\ \(0\)\
\-\ barium\\:\\ 0\\.012403262244025725\ \(0\)\
\-\ noted\\:\\ 0\\.012128270589536489\ \(0\)\
\-\ dilation\\:\\ 0\\.012059960123306745\ \(0\)\
\-\ major\\:\\ 0\\.011961787001082221\ \(0\)\
\-\ is\\:\\ 0\\.011784537271536165\ \(0\)\
\-\ this\\:\\ 0\\.011510625309151295\ \(0\)\
\-\ per\\:\\ 0\\.01119863655309183\ \(0\)\
\-\ development\\:\\ 0\\.01114301863221478\ \(0\)\
\-\ frequently\\:\\ 0\\.011088415076676513\ \(0\)\
\-\ have\\:\\ 0\\.011080467535120311\ \(0\)\
\-\ admitted\\:\\ 0\\.011052558217255207\ \(0\)\
\-\ infectious\\:\\ 0\\.010999565471448617\ \(0\)\
\-\ etiology\\:\\ 0\\.010829405367367284\ \(0\)\
\-\ \\(\\:\\ 0\\.010813798297063781\ \(0\)\
\-\ defined\\:\\ 0\\.010780187623824888\ \(0\)\
\-\ best\\:\\ 0\\.0107639598769107\ \(0\)\
\-\ \\)\\:\\ 0\\.010681701977744089\ \(0\)\
\-\ thin\\:\\ 0\\.010515609329064141\ \(0\)\
\-\ initially\\:\\ 0\\.010413114803189162\ \(0\)\
\-\ diagnostic\\:\\ 0\\.010138241901233705\ \(0\)\
\-\ also\\:\\ 0\\.010087542477066775\ \(0\)\
\-\ \\#\\:\\ 0\\.010034989877068528\ \(0\)\
\-\ marked\\:\\ 0\\.009984669163546428\ \(0\)\
\-\ \\?\\:\\ 0\\.009984669163546428\ \(0\)\
\-\ causes\\:\\ 0\\.009959822448532371\ \(0\)\
\-\ second\\:\\ 0\\.009826733339038857\ \(0\)\
\-\ http\\:\\ 0\\.009687989814312204\ \(0\)\
\-\ hospital\\:\\ 0\\.00963202534421594\ \(0\)\
\-\ dilated\\:\\ 0\\.00929668085805877\ \(0\)\
\-\ risk\\:\\ 0\\.009267085770536188\ \(0\)\
\-\ \\&\\:\\ 0\\.008986191293836623\ \(0\)\
\-\ because\\:\\ 0\\.008950653642473197\ \(0\)\
\-\ fever\\:\\ 0\\.008656474929796307\ \(0\)\
\-\ initial\\:\\ 0\\.008477790848141641\ \(0\)\
\-\ disease\\:\\ 0\\.008363697851591044\ \(0\)\
\-\ positive\\:\\ 0\\.008302052665521309\ \(0\)\
\-\ usually\\:\\ 0\\.007769246269062153\ \(0\)\
\-\ as\\:\\ 0\\.0077399850652342984\ \(0\)\
\-\ infection\\:\\ 0\\.007437175371475471\ \(0\)\
\-\ wall\\:\\ 0\\.007410656048619001\ \(0\)\
\-\ y\\.o\\:\\ 0\\.007384369558642815\ \(0\)\
\-\ s\\:\\ 0\\.007337627745852057\ \(0\)\
\-\ two\\:\\ 0\\.007327339034778461\ \(0\)\
\-\ \\,\\:\\ 0\\.007294582603759241\ \(0\)\
\-\ weeks\\:\\ 0\\.007261310649404636\ \(0\)\
\-\ following\\:\\ 0\\.007261310649404636\ \(0\)\
\-\ an\\:\\ 0\\.0070758375106870055\ \(0\)\
\-\ history\\:\\ 0\\.007067152920401698\ \(0\)\
\-\ cm\\:\\ 0\\.0068621440653203174\ \(0\)\
\-\ these\\:\\ 0\\.006658217640592336\ \(0\)\
\-\ patients\\:\\ 0\\.006621480836425228\ \(0\)\
\-\ for\\:\\ 0\\.006548875586611214\ \(0\)\
\-\ symptoms\\:\\ 0\\.0063762199907129915\ \(0\)\
\-\ in\\:\\ 0\\.006308341768566691\ \(0\)\
\-\ increased\\:\\ 0\\.006258936472454059\ \(0\)\
\-\ pain\\:\\ 0\\.006249150703776855\ \(0\)\
\-\ \\;\\:\\ 0\\.0060641352947682445\ \(0\)\
\-\ associated\\:\\ 0\\.006037313059603898\ \(0\)\
\-\ woman\\:\\ 0\\.005909889064338043\ \(0\)\
\-\ other\\:\\ 0\\.005897121403300744\ \(0\)\
\-\ can\\:\\ 0\\.005803060935536137\ \(0\)\
\-\ present\\:\\ 0\\.005778469323148745\ \(0\)\
\-\ it\\:\\ 0\\.005751043067464122\ \(0\)\
\-\ 2\\:\\ 0\\.005509294899732175\ \(0\)\
\-\ but\\:\\ 0\\.005456596709681251\ \(0\)\
\-\ of\\:\\ 0\\.005232206622664151\ \(0\)\
\-\ to\\:\\ 0\\.005114588125065704\ \(0\)\
\-\ the\\:\\ 0\\.004967040168992544\ \(0\)\
\-\ has\\:\\ 0\\.004804490929623587\ \(0\)\
\-\ are\\:\\ 0\\.0034876463249389274\ \(0\)\
\-\ \\:\\:\\ 0\\.0033840563353013924\ \(0\)\
\-\ and\\:\\ 0\\.0026947455947936893\ \(0\)\
\-\ a\\:\\ 0\\.0023748491126862354\ \(0\)\
\-\ on\\:\\ 0\\.0021673383603755332\ \(0\)\
\-\ \\.\\:\\ 0\\.0021257207243919924\ \(0\)\
\-\ with\\:\\ 0\\.001401247617842991\ \(0\)\
